Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Pulmonary arterial hypertension (PAH) is a progressive vasculopathy characterized by remodeling of small pulmonary arteries, elevated pulmonary arterial pressure, and right-heart failure. Heterozygous mutations in the bone morphogenetic protein receptor type II gene (BMPR2) underlie most heritable PAH cases and a significant fraction of idiopathic PAH, establishing BMPR2 as the major gene predisposing to PAH. BMPR2 encodes a transforming growth factor-β superfamily type II receptor that signals via SMAD1/5/8 and non-SMAD pathways to regulate vascular cell proliferation, apoptosis, and inflammation. Loss of BMPR-II function disrupts pulmonary endothelial and smooth muscle homeostasis, leading to the PAH phenotype.
Genetic evidence for BMPR2 involvement is robust. Heterozygous BMPR2 mutations have been identified in over 210 independent PAH probands, including familial and sporadic cases ([PMID:16429395]). In 47 FPAH families, >70 distinct BMPR2 mutations—nonsense, frameshift, splice-site, missense, and large deletions—were reported, with multigenerational segregation supporting autosomal-dominant inheritance and reduced penetrance ([PMID:11115378]). Vasoreactivity studies in 67 patients demonstrated that 27 BMPR2 mutation carriers show marked impairment in pulmonary artery pressure response to exercise and hypoxia (3.7% vs 35% responders; [PMID:16717148]). These data collectively satisfy ClinGen criteria for a Definitive gene-disease association.
BMPR2 mutations act via haploinsufficiency and dominant-negative mechanisms. Frameshift and nonsense mutations predict premature termination codons subject to nonsense-mediated decay, reducing receptor dosage. Missense mutations in the ligand-binding and kinase domains disrupt receptor trafficking to the cell surface or impair kinase activity, as confirmed by in vitro assays. A recurrent truncating allele, c.47G>A (p.Trp16Ter), abolishes receptor signaling and segregates with disease in multiple families ([PMID:15687131]).
Functional assays corroborate pathogenesis. In vitro expression of BMPR2 mutants reveals endoplasmic reticulum retention of cysteine-substituted receptors and loss of SMAD1/5 phosphorylation upon BMP4 stimulation. Non-SMAD pathways, including p38-MAPK activation, are dysregulated by mutant alleles, promoting endothelial apoptosis and smooth muscle proliferation. Chemical chaperones restore mutant receptor trafficking and partially rescue downstream SMAD signaling, highlighting a potential therapeutic avenue ([PMID:18647753]).
In vivo models mirror human PAH. Transgenic mice with endothelial-specific expression of Bmpr2delx4+ or Bmpr2R899X exhibit elevated right ventricular systolic pressure, vascular muscularization, thrombosis, inflammation, and apoptosis in pulmonary microvasculature ([PMID:21696628]). These phenotypes confirm that BMPR2 mutation alone suffices to induce key features of PAH and validate mechanistic insights from cellular studies.
Conflicting evidence is scarce but underscores incomplete penetrance: some mutation carriers remain asymptomatic lifelong, suggesting additional genetic or environmental modifiers influence disease manifestation. Co-occurrence of EIF2AK4 mutations in BMPR2 carriers supports a two-hit model for full penetrance, indicating complexity in clinical risk prediction.
Together, genetic and experimental data define BMPR2 mutations as a definitive cause of heritable PAH. Clinical genetic testing for BMPR2 variants guides diagnosis, family counseling, and may inform therapeutic strategies such as targeted chaperone therapy. Key take-home: BMPR2 haploinsufficiency drives PAH pathogenesis, and normalization of BMPR-II function represents a promising intervention strategy.
Gene–Disease AssociationDefinitiveOver 210 probands, multigenerational segregation in 47 families, concordant functional and animal model data Genetic EvidenceStrong
Functional EvidenceStrongCellular assays show loss of SMAD signaling and receptor trafficking; endothelial-specific mouse models replicate PAH |